Theories of the pathogenesis of inclusion body myositis

Current Rheumatology Reports

Volumn 12, Issue 3, 2010, Pages 221-228

  Greenberg, Steven A ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Inclusion body myositis

Indexed keywords

AMYLOID BETA PROTEIN; BIOLOGICAL MARKER; GAMMA INTERFERON; LITHIUM SALT; TAR DNA BINDING PROTEIN; TAU PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

B LYMPHOCYTE; CLINICAL TRIAL; DISEASE MODEL; GENE OVEREXPRESSION; HUMAN; IMMUNE SYSTEM; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INCLUSION BODY MYOSITIS; INFLAMMATION; MUSCLE INJURY; NONHUMAN; PATHOGENESIS; POLYMYOSITIS; PROTEIN LOCALIZATION; REVIEW; T LYMPHOCYTE; TAUOPATHY; THEORY;

ANIMALS; BIOLOGICAL MARKERS; DISEASE MODELS, ANIMAL; HUMANS; MUSCLE FIBERS, SKELETAL; MYOSITIS, INCLUSION BODY; SKIN;

EID: 77953476411     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-010-0102-5     Document Type: Review

References (51)

1. Yunis EJ, Samaha FJ: Inclusion body myositis. Lab Invest 1971, 25:240-248.
2. Machado P, Miller A, Holton J, Hanna M: Sporadic inclusion body myositis: an unsolved mystery. Acta Reumatol Port 2009, 34:161-182. This is a comprehensive review of many aspects of IBM.
3. Karpati G, O'Ferrall EK: Sporadic inclusion body myositis: pathogenic considerations. Ann Neurol 2009, 65:7-11.
4. Greenberg SA: Inclusion body myositis: review of recent literature. Curr Neurol Neurosci Rep 2009, 9:83-89.
5. Askanas V, Engel WK, Nogalska A: Inclusion body myositis: a degenerative muscle disease associated with intra-muscle fiber multi-protein aggregates, proteasome inhibition, endoplasmic reticulum stress and decreased lysosomal degradation. Brain Pathol 2009, 19:493-506.
6. Needham M, Mastaglia FL: Sporadic inclusion body myositis: a continuing puzzle. Neuromuscul Disord 2008, 18:6-16. This is a thoughtful review of IBM mechanistic theories.
7. Greenberg SA: Inflammatory myopathies: disease mechanisms. Curr Opin Neurol 2009, 22:516-523. This is a review of inflammatory myopathy disease mechanisms that focuses on dermatomyositis and IBM.
8. Askanas V, Engel WK: Inclusion-body myositis: a myodegenerative conformational disorder associated with Abeta, protein misfolding, and proteasome inhibition. Neurology 2006, 66(2 Suppl 1):S39-S48.
9. Greenberg SA: How citation distortions create unfounded authority: analysis of a citation network. BMJ 2009, 339:b2680. This article rigorously demonstrates how distortions in the scholarly process of citation may create belief in unfounded claims, with particular attention paid to claims regarding A/β in IBM.
10. Muth IE, Barthel K, Bahr M, et al.: Proinflammatory cell stress in sporadic inclusion body myositis muscle: overexpression of alphaB-crystallin is associated with amyloid precursor protein and accumulation of beta-amyloid. J Neurol Neurosurg Psychiatry 2009, 80:1344-1349.
11. Greenberg SA: Comment on 'Interrelation of inflammation and APP in sIBM: IL-1 {beta} induces accumulation of {beta}-amyloid in skeletal muscle.' Brain 2009, 132:e106.
12. Askanas V, Sarkozi E, Bilak M, et al.: Human muscle macrophages express beta-amyloid precursor and prion proteins and their mRNAs. Neuroreport 1995, 6:1045-1049.
13. Sarkozi E, Askanas V, Johnson SA, et al.: Expression of beta-amyloid precursor protein gene is developmentally regulated in human muscle fibers in vivo and in vitro. Exp Neurol 1994, 128:27-33.
14. Sarkozi E, Askanas V, Johnson SA, et al.: beta-Amyloid precursor protein mRNA is increased in inclusion-body myositis muscle. Neuroreport 1993, 4:815-818.
15. Nalbantoglu J, Karpati G, Carpenter S: Conspicuous accumulation of a single-stranded DNA binding protein in skeletal muscle fibers in inclusion body myositis. Am J Pathol 1994, 144:874-882.
16. Greenberg SA, Sanoudou D, Haslett JN, et al.: Molecular profiles of inflammatory myopathies. Neurology 2002, 59:1170-1182.
17. Schmidt J, Barthel K, Wrede A, et al.: Interrelation of inflammation and APP in sIBM: IL-1 beta induces accumulation of beta-amyloid in skeletal muscle. Brain 2008, 131:1228-1240.
18. Fukuchi K, Pham D, Hart M, et al.: Amyloid-beta deposition in skeletal muscle of transgenic mice: possible model of inclusion body myopathy. Am J Pathol 1998, 153:1687-1693.
19. Jin LW, Hearn MG, Ogburn CE, et al.: Transgenic mice over-expressing the C-99 fragment of betaPP with an alpha-secretase site mutation develop a myopathy similar to human inclusion body myositis. Am J Pathol 1998, 153:1679-1686.
20. Sugarman MC, Yamasaki TR, Oddo S, et al.: Inclusion body myositis-like phenotype induced by transgenic overexpression of beta APP in skeletal muscle. Proc Natl Acad Sci USA 2002, 99:6334-6339.
21. Strazielle C, Dumont M, Fukuchi K, Lalonde R: Transgenic mice expressing the human C99 terminal fragment of betaAPP: effects on cytochrome oxidase activity in skeletal muscle and brain. J Chem Neuroanat 2004, 27:237-246.
22. Kitazawa M, Green KN, Caccamo A, LaFerla FM: Genetically augmenting Abeta42 levels in skeletal muscle exacerbates inclusion body myositis-like pathology and motor deficits in transgenic mice. Am J Pathol 2006, 168:1986-1997.
23. Moussa CE, Fu Q, Kumar P, et al.: Transgenic expression of betaAPP in fast-twitch skeletal muscle leads to calcium dyshomeostasis and IBM-like pathology. FASEB J 2006, 20:2165-2167.
24. Sugarman MC, Kitazawa M, Baker M, et al.: Pathogenic accumulation of APP in fast twitch muscle of IBM patients and a transgenic model. Neurobiol Aging 2006, 27:423-432.
25. Kitazawa M, Trinh DN, LaFerla FM: Inflammation induces tau pathology in inclusion body myositis model via glycogen synthase kinase-3beta. Ann Neurol 2008, 64:15-24.
26. Rebolledo DL, Minniti AN, Grez PM, et al.: Inclusion body myositis: a view from the Caenorhabditis elegans muscle. Mol Neurobiol 2008, 38:178-198.
27. Salajegheh M, Pinkus JL, Nazareno R, et al.: Nature of "Tau" immunoreactivity in normal myonuclei and inclusion body myositis. Muscle Nerve 2009, 40:520-528. The identity of SMI-31 immunoreactive material widely interpreted as phosphorylated tau was shown to likely be neurofilament H.
28. Maurage CA, Bussière T, Sergeant N, et al.: Tau aggregates are abnormally phosphorylated in inclusion body myositis and have an immunoelectrophoretic profile distinct from other tauopathies. Neuropathol Appl Neurobiol 2004, 30:624-634.
29. Delaunay A, Bromberg KD, Hayashi Y, et al.: The ER-bound RING finger protein 5 (RNF5/RMA1) causes degenerative myopathy in transgenic mice and is deregulated in inclusion body myositis. PLoS ONE 2008, 3:e1609.
30. Greenberg SA: Proposed immunologic models of the inflammatory myopathies and potential therapeutic implications. Neurology 2007, 69:2008-2019.
31. Engel AG, Arahata K: Monoclonal antibody analysis of mononuclear cells in myopathies. II: Phenotypes of autoinvasive cells in polymyositis and inclusion body myositis. Ann Neurol 1984, 16:209-215.
32. Greenberg SA, Bradshaw EM, Pinkus JL, et al.: Plasma cells in muscle in inclusion body myositis and polymyositis. Neurology 2005, 65:1782-1787.
33. (Published erratum appears in Neurology 2006, 66:493.)
34. Bradshaw EM, Orihuela A, McArdel SL, et al.: A local antigen-driven humoral response is present in the inflammatory myopathies. J Immunol 2007, 178:547-556. The intramuscular B-cell response in IBM was shown to be antigen driven, laying the groundwork for future antibody-based antigen discovery.
35. Salajegheh M, Lin YY, Parker KC, et al.: Using humoral immunity for the identification of candidate antigens in inclusion body myositis [abstract]. Neurology 2007, 68(Suppl 1): A361.
36. Banwell BL, Engel AG: AlphaB-crystallin immunolocalization yields new insights into inclusion body myositis. Neurology 2000, 54:1033-1041.
37. Chou SM: Myxovirus-like structures in a case of human chronic polymyositis. Science 1967, 158:1453-1455.
38. Chou SM: Myxovirus-like structures and accompanying nuclear changes in chronic polymyositis. Arch Pathol 1968, 86:649-658.
39. Carpenter S, Karpati G, Heller I, Eisen A: Inclusion body myositis: a distinct variety of idiopathic inflammatory myopathy Neurology 1978, 28:8-17.
40. Carpenter S: Inclusion body myositis, a review. J Neuropathol Exp Neurol 1996, 55:1105-1114.
41. Karpati G, Carpenter S: Pathology of the inflammatory myopathies. Baillieres Clin Neurol 1993, 2:527-556.
42. Greenberg SA, Pinkus JL, Amato AA: Nuclear membrane proteins are present within rimmed vacuoles in inclusion-body myositis. Muscle Nerve 2006, 34:406-416.
43. Weihl CC, Temiz P, Miller SE, et al.: TDP-43 accumulation in inclusion body myopathy muscle suggests a common pathogenic mechanism with frontotemporal dementia. J Neurol Neurosurg Psychiatry 2008, 79:1186-1189. This article found sarcoplasmic TDP-43, a protein normally seen only in nuclei, in biopsy samples from patients with IBM and valosin-containing protein mutation inclusion body myopathies.
44. Salajegheh M, Pinkus JL, Taylor JP, et al.: Sarcoplasmic redistribution of nuclear TDP-43 in inclusion body myositis. Muscle Nerve 2009, 40:19-31. TDP-43 presence in IBM was quantitated in relation to other reported biomarkers. The relation between this nucleic acid-binding protein and nuclear abnormalities is discussed.
45. Küsters B, van Hoeve BJ, Schelhaas HJ, et al.: TDP-43 accumulation is common in myopathies with rimmed vacuoles. Acta Neuropathol 2009, 117:209-211.
46. Olivé M, Janué A, Moreno D, et al.: TAR DNA-binding protein 43 accumulation in protein aggregate myopathies. J Neuropathol Exp Neurol 2009, 68:262-273.
47. Capsoni S, Ruberti F, Di Daniel E, Cattaneo A: Muscular dystrophy in adult and aged anti-NGF transgenic mice resembles an inclusion body myopathy. J Neurosci Res 2000, 59:553-560.
48. Chen X, Ghribi O, Geiger JD: Rabbits fed cholesterol-enriched diets exhibit pathological features of inclusion body myositis. Am J Physiol Regul Integr Comp Physiol 2008, 294:R829-R835.
49. Kitazawa M, Vasilevko V, Cribbs DH, LaFerla FM: Immunization with amyloid-beta attenuates inclusion body myositis-like myo-pathology and motor impairment in a transgenic mouse model. J Neurosci 2009, 29:6132-6141.
50. Koistinen H, Prinjha R, Soden P, et al.: Elevated levels of amyloid precursor protein in muscle of patients with amyotrophic lateral sclerosis and a mouse model of the disease. Muscle Nerve 2006, 34:444-450.
51. Yang CC, Alvarez RB, Engel WK, Askanas V: Increase of nitric oxide synthases and nitrotyrosine in inclusion-body myositis. Neuroreport 1996, 8:153-158.